W hen a patient presents with a primary symptom of cognitive decline, an important and challenging component of the diagnostic process is to determine whether the disorder is reversible. Misdiagnosis of a potentially reversible condition as a progressive neurodegenerative OBJECTIVE: To define the diagnostic characteristics and predictors of treatment response in patients with suspected autoimmune dementia.
PATIENTS AND METHODS:
Between January 1, 2002, and January 1, 2009, 72 consecutive patients received immunotherapy for suspected autoimmune dementia. Their baseline clinical, radiologic, and serologic characteristics were reviewed and compared between patients who were responsive to immunotherapy and those who were not. Patients were classified as responders if the treating physician had reported improvement after immunotherapy (documented in 80% by the Kokmen Short Test of Mental Status, neuropsychological testing, or both).
RESULTS:
Initial immunotherapeutic regimens included methylprednisolone in 56 patients (78%), prednisone in 12 patients (17%), dexamethasone in 2 patients (3%), intravenous immune globulin in 1 patient (1%), and plasma exchange in 1 patient (1%). Forty-six patients (64%) improved, most in the first week of treatment. Thirty-five percent of these immunotherapy responders were initially diagnosed as having a neurodegenerative or prion disorder. Pretreatment and posttreatment neuropsychological score comparisons revealed improvement in almost all cognitive domains, most notably learning and memory. Radiologic or electroencephalographic improvements were reported in 22 (56%) of 39 patients. Immunotherapy responsiveness was predicted by a subacute onset (P<.001), fluctuating course (P<.001), tremor (P=.007), shorter delay to treatment (P=.005), seropositivity for a cation channel complex autoantibody (P=.01; neuronal voltage-gated potassium channel more than calcium channel or neuronal acetylcholine receptor), and elevated cerebrospinal fluid protein (>100 mg/dL) or pleocytosis (P=.02). Of 26 immunotherapy-responsive patients followed up for more than 1 year, 20 (77%) relapsed after discontinuing immunotherapy. disorder on the basis of the presumption of irreversibility has devastating consequences for the patient and family. Traditionally, neurologists have been reluctant to consider a diagnosis of autoimmune dementia in the absence of delirium. However, despite being poorly defined, some newonset dementias are immunotherapyresponsive. 1 Recent reports support the concept of a broader spectrum of autoimmune cognitive impairment than "limbic encephalitis." [2] [3] [4] Case series reports and clinical-serologic observations have demonstrated that progressive dementia without delirium may represent an autoimmune neurologic disorder. 3, 4 Reported clinical features suggesting an autoimmune basis for dementia include a subacute onset with a rapidly progressive, often fluctuating course; coexisting organspecific autoimmunity; and inflammatory spinal fluid. [2] [3] [4] [5] [6] [7] [8] The confusing nomenclature applied to autoimmune encephalopathies with cognitive impairment reflects the evolution of understanding of these disorders. Customary classification has been based on a syndromic presentation (eg, Morvan syndrome 9 or progressive encephalomyelopathy with rigidity and myoclonus 10 ), a specific serologic marker (eg, voltage-gated potassium channel [VGKC] complex antibody-associated encephalopathy 6 or thyroid autoantibody-associated [Hashimoto] encephalopathy 2, 11 ), or histopathologic findings (eg, nonvasculitic For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a .
autoimmune meningoencephalitis). 12 The potential for reversibility by immunotherapy unifies these disorders. The terms encephalopathy, dementia, delirium, and cognitive impairment all pertain to impaired cognition, but the definitions and implications for each term are slightly different. We will refer to these disorders henceforth as autoimmune dementia to emphasize that altered cognition is the principal clinical presentation and that autoimmunity is the underlying pathogenic mechanism.
With the goal of defining autoimmune dementias in terms of diagnostic characteristics and predictors of treatment response in patients presenting to Mayo Clinic in Rochester, MN, we established a multidisciplinary Autoimmune Dementia and Encephalopathy Study Group consisting of physicians from the Department of Neurology (Division of Multiple Sclerosis and Autoimmune Neurological Disorders and Division of Behavioral Neurology) and Department of Laboratory Medicine and Pathology (Neuroimmunology Laboratory). This article describes the clinical course and predictors of improvement in 72 consecutive patients presenting with dementia or encephalopathy who were evaluated between January 1, 2002, and January 1, 2009, and were selected for a trial of immunotherapy because an autoimmune basis for their condition was strongly suspected.
PATIENTS AND METHODS
The study used Mayo Clinic's computerized central diagnostic index and was approved by the Mayo Clinic Institutional Review Board. We reviewed 202 medical records of patients seen from January 1, 2002, to January 1, 2009, who fulfilled 3 criteria: (1) the recorded diagnosis included the search terms cognitive, dementia, and/or encephalopathy or encephalitis; (2) Seventy-two (36%) of the 202 identified patients met the following inclusion criteria: (1) a neurologic presentation that was predominantly cognitive, (2) an autoimmune basis suspected and a trial of immunotherapy initiated, and (3) pretreatment and posttreatment neurologic assessment at Mayo Clinic. We excluded the remaining 130 patients (64%) for the following reasons: lack of a cognitive presentation, 28 patients; lack of surveillance for a therapeutic response, 18 patients; or no immunotherapy prescribed, 84 patients. Of the 84 patients who did not receive immunotherapy, 42 (50%) were assigned a different diagnosis after subsequent evaluation (eg, neurodegenerative dementia, central nervous system infection, cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy, depression, Rasmussen encephalitis, trauma, developmental disorder); 26 (31%) proved to have search terms unrelated to the cognitive disorder (eg, resolving leg pain and dementia); 12 (14%) had an incomplete evaluation due to a lack of follow-up; 3 (4%) had a complete evaluation but withdrew from the study before planned immunotherapy could be administered; and 1 (1%) had terminal cancer, which contraindicated immunotherapy.
Evaluation of Cognition
Sixty-eight patients (94%) completed the Kokmen Short Test of Mental Status (STMS) during their evaluation; 56 patients were tested before treatment, and 41 were tested before and after an immunotherapy trial. 13, 14 The Kokmen STMS assesses and scores orientation (8 points), attention (7 points), learning (4 points), calculation (4 points), abstraction (3 points), construction (4 points), information (4 points), and recall (4 points). The maximum score is 38 points.
Neuropsychological test results were available for 51 patients (34 were retested after immunotherapy). A clinical neuropsychologist (M.R.T.) analyzed all baseline test results and compared results before and after immunotherapy. The following cognitive domains were evaluated: (1) 22, 23 ); and (6) overall cognition with the Dementia Rating Scale. 24 In TMT A, the time taken for a participant to connect the dots of 25 numbers scattered on a screen is assessed. In TMT B, the time taken for a participant to connect the dots of 25 numbers and 25 letters, alternating between the two, is assessed (for example: 1, A, 2, B…). Trail-Making Test B is considered more difficult and a better test of brain function than TMT A. 25 To facilitate comparison between different indices, the AVLT, COWAT, CFT, and TMT scores were converted to Mayo Older Americans Normative Studies scaled scores. A mean score of 10 points, with a standard deviation of 3 points, is normal. 21, 26, 27 For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a . (24) 10 (22) 7 (27) .77 Family history of autoimmunity 36 (50) 25 (54) 11 (42) . For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a .
Jakob disease, 4; Lewy body disease, 3; mild cognitive impairment, 2; semantic dementia, 1). Cognitive Assessments Before and After Treatment. Posttherapy improvements in cognition were documented in 46 (64%) of 72 patients: by both Kokmen STMS score and neuropsychological testing, 17; Kokmen STMS score alone, 14; neuropsychological testing alone, 6; and physician-reported improvement by neurologic assessment alone, 9. Improvements were evident within 1 week in 36 (78%) of the responders and within 4 weeks in 46 (100%). By Kokmen STMS score, the mean improvement ( Figure 1 ) was 9 points (SD, ±7 points; P<.001; maximum score, 38 points); the mean ± SD pretherapy score was 23±9 points; and the mean ± SD posttherapy score was 33±4 points. Neuropsychological scores revealed that individual patients improved in almost all cognitive domains after immunotherapy (P<.01, paired t test; Table 3 ). Improvements were most notable in learning and memory and were more marked in patients who were seropositive for VGKC complex antibodies (6 of 10 seropositive patients; Figure 2 ).
Maintenance Immunotherapy and Relapse. Clinical relapse occurred after discontinuing or tapering initial immunotherapy in 20 (77%) of 26 patients who were followed up for 1 year or longer and had initially responded to immunotherapy. Long-term immunosuppression was instituted in 35 (76%) of 46 patients, usually IV corticosteroids or IVIG with or without a corticosteroid-sparing agent. Most patients were reevaluated every 3 to 6 months, and, depending on their . Symmetric confluent T2 signal abnormality in the white matter of both hemispheres (B1) decreased after treatment with IV methylprednisolone (B2). C, 60-year-old man (patient 41 in Appendix 1) had memory, language, and gait problems and was seropositive for both striational and glutamic acid decarboxylase-65 antibodies. Axial T1 magnetic resonance imaging with contrast demonstrated periventricular vessel enhancement (C1) and resolution after treatment (C2). D, 53-year-old woman (patient 29 in Appendix 1) had memory loss, hallucinations, and subsequent seizure; cerebrospinal fluid protein was elevated (>100 mg/dL), and she was seropositive for thyroid peroxidase antibodies and neuronal and muscle acetylcholine receptor antibodies. Axial FLAIR images show diffusely increased T2 signal in the midbrain (D1), which improved after treatment with IV methylprednisolone (D2). Multiple myeloma was diagnosed 18 months after neurologic presentation.
Positron emission tomographic imaging: Brain reconstructions (brighter color represents regions of hypometabolism) in a 58-year-old man (patient 21 in Appendix 1) who presented with personality change and memory problems and had elevated cerebrospinal fluid protein (>100 mg/dL). Hypometabolism, predominantly frontal and temporal (E1), improved after treatment with IV methylprednisolone (E2).
Single-photon emission computed tomographic brain imaging: Brain neuroimaging in a 35-year-old man (patient 22 in Appendix 1) who presented with vertigo and memory problems, had multiple coexisting autoimmune conditions, and was seropositive for muscle acetylcholine receptor and striational antibodies. Diffuse decrease in uptake in frontotemporoparietal regions (F1) was markedly improved globally after treatment with IV methylprednisolone (F2).
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Resolution of epileptiform activity was seen in 1 (14%) of 7 patients after treatment with combinations of immunotherapy and antiepileptic medications. Neuropathology and Autopsy Findings. In 1 patient, right temporal lobe biopsy demonstrated a grade 3 astrocytoma. In another patient, autopsy revealed widespread spongiform change, mild gliosis, and proteinase-resistant scrapie prion protein consistent with Creutzfeldt-Jakob disease. In a third patient, autopsy revealed neurofibrillary tangles, neuritic plaques, and amyloid angiopathy plus widespread brainstem, limbic, and cortical Lewy bodies, pale bodies, and Lewy neurites, as is consistent with mixed Alzheimer and Lewy body disease.
faCtorS aSSoCiatEd With immunothErapy rESponSivEnESS
The mean interval from symptom onset to first immunotherapy treatment was 11 months in responders and 25 months in nonresponders (P<.001). Predictors of response to immunotherapy were identified by univariate logistic regression analysis and are summarized in Table 4 (with odds ratios and 95% confidence intervals): subacute onset (P<.001); fluctuating course (P<.001); tremor (P=.007); headache (P=.06); inflammatory CSF (P=.02); any neural autoantibody (P=.03); cation channel neural autoantibody (P=.01); and VGKC complex antibodies alone (P=.05).
Predictors of immunotherapy nonresponsiveness on the univariate logistic regression analysis included a family his-FIGURE 4. Electroencephalogram (EEG) before and after immunotherapy in patients with immunotherapy-responsive cognitive disorders. A, EEG in a 60-year-old man (patient 31 in Appendix 1) who presented with memory difficulty and inattention and had elevated cerebrospinal fluid protein (>100 mg/dL) and voltage-gated potassium channel complex autoantibody. Before treatment, the EEG showed a left anterior temporal lobe seizure (A1) and left temporal intermittent rhythmic delta and sharp wave activity (A2). This resolved after treatment with both a loading dose of phenytoin and intravenous methylprednisolone (A3). Of note, this patient had corresponding improvements in mesiotemporal signal abnormality on magnetic resonance imaging and resolution of left temporal hypermetabolism on positron emission tomography. B, EEG in a 71-year-old man (patient 13 in Appendix 1) who presented with subacute, rapidly progressing memory problems mimicking Creutzfeldt-Jakob disease. He was seropositive for thyroid peroxidase antibody and had inflammatory cerebrospinal fluid. Note severe, diffuse theta and delta wave slowing maximal over the left hemisphere (B1), and improvement with mild background slowing (7-8 Hz posterior alpha) after treatment with intravenous methylprednisolone (B2).
For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a . α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid, 35 or γ-aminobutyric type B receptor reactivity. 36 One patient's serum contained a novel IgG that bound selectively to the hippocampus and cerebral cortex (Figure 5 , F; Appendix 1: patient 14).
DISCUSSION
All patients for whom we describe clinical, serologic, and imaging findings had a predominantly cognitive clinical presentation that the treating physician suspected to have an autoimmune basis. The high frequency and striking extent of objective improvements in cognition after immunotherapy warrant emphasis. The assignment of an initial diagnosis of a neurodegenerative or prion disease to 35% of patients who subsequently improved after immunotherapy suggests that autoimmune dementia may be underrecognized and the potential benefit of immunotherapy missed in many patients. Although population-based studies are lacking for the incidence and prevalence of autoimmune dementia, 20% of dementia cases occurring in patients younger than 45 years presenting to an academic medical center were reported to have an autoimmune or inflammatory cause. 37 Documentation of cognitive deficits by mental status testing and standard neuropsychological testing was particularly helpful in objective measurement of improvements after immunotherapy. The data we present refute reliance on impaired attention as the primary domain of cognitive impairment on mental status testing. All areas of cognition were impaired, but in comparison with other cognitive deficits, deficits in recall were more frequent and severe and showed greater improvements after immunotherapy. This observation is consistent with MRI abnormalities often being located in mesiotemporal lobes.
The design of our study allowed the identification of clues that might predict immunotherapy responsiveness. Important clinical predictors of response to immunotherapy included a subacute onset, fluctuating course, and the physical finding of tremor. The detection of myoclonus on examination approached but did not reach statistical significance. In an autoimmune context, small-amplitude generalized myoclonus sometimes is mistaken clinically for tremor. 38 Patients who benefited from immunotherapy were 8 times more likely to have headache than those who did not respond. Although not statistically significant (P=.06), headache may be a clue to an immune-mediated etiology for dementia. This finding warrants further investigation in larger studies. In evaluating a patient with cognitive symptoms, any of these clinical features heightens the suspicion for an immune-mediated dementia and warrants consideration of an immunotherapy trial.
The significant correlation of CSF protein elevation (>100 mg/dL) or pleocytosis with response to immunotherapy justifies analysis of CSF in evaluating a suspected autoimmune dementia. Other CSF markers of inflammation (raised IgG index or synthesis rate or excess oligoclonal bands) favor an autoimmune rather than neurodegenerative dementia, but their frequency in responders and nonresponders did not differ significantly in this study. Supernumerary CSF oligoclonal bands have been reported in 7% of pathologically proven neurodegenerative conditions. 39 In patients who responded to immunotherapy, brain biopsy revealed gliosis and perivascular lymphocytic infiltration similar to findings described in patients with nonvasculitic autoimmune inflammatory meningoencephalitis. 40 Brain biopsy should be considered in patients with an atypical dementia syndrome that is suspected to have a nondegenerative etiology but lacks objective evidence of autoimmunity. The 4 immunotherapy-responsive patients who had pathologic findings consistent with Alzheimer disease with amyloid angiopathy were especially informative. It is conceivable that 2 etiologic processes contributed to their cognitive impairment or, alternatively, that immunotherapy suppressed the amyloid angiopathy or an inflammatory component early in the course of an evolving neurodegenerative disorder.
Detection of neural antibodies, especially neuron-specific cation channel complex autoantibodies, was another laboratory-based clue predicting a favorable response to immunotherapy. We identified autoantibodies targeting the VGKC complex, voltage-gated calcium channels, or a neuronal AChR in 43% of responders and 10% of nonresponders. These findings justify a comprehensive serologic evaluation for neural autoantibodies in investigating a patient with suspected neurodegenerative dementia who has any atypical features. Cognitive impairment is a recognized association of several neuron-specific autoantibodies: the VGKC complex, 6 ,41 the NMDA receptor, 8 and neuronal AChR antibodies. 7 Because neoplasia is found in 33% to 80% of seropositive patients, 6 ,42 detection of these autoantibodies justifies a search for cancer. In the current study, cancer was identified in 3 seropositive patients: 1 with multiple myeloma, 1 with colonic adenocarcinoma, For personal use. Mass reproduce only with permission from Mayo Clinic Proceedings a .
and 1 with small cell lung carcinoma. Thus, the detection of a neuron-specific autoantibody in a patient with autoimmune dementia may lead to the diagnosis of an unsuspected neoplasm. Despite the reported association of TPO antibodies and autoimmune encephalopathies, detection of thyroid antibodies was not predictive of immunotherapy responsiveness in patients in this study. This likely reflects the high prevalence of TPO antibodies in the general population (2%-10% in younger adults and 5%-20% in healthy older adults). [43] [44] [45] We regard as obsolete the continued use of the term Hashimoto encephalopathy in patients with autoimmune dementia or autoimmune encephalopathy. Detection of TPO antibodies reflects a predisposition to an autoimmune neurologic disorder but does not imply a pathogenic role for those autoantibodies. We anticipate that continuing advances in autoimmune neurology will identify new neuron-specific autoantibodies as the cause of reversible cognitive decline in these patients.
A shorter delay from symptom onset to initiation of therapy for autoimmune dementia increased the likelihood of response to immunotherapy. This emphasizes the importance of early and correct diagnosis and prompt treatment. Evidence-based outcomes for treatment of autoimmune dementia are limited and confined to case reports and small case series. 3, 39, 46 The improvements we observed after acute treatments were often not sustained. Most patients in our cohort had a clinical relapse on cessation or reduction of immunotherapy. Careful selection of patients for long-term immunotherapy is important, given the risk of serious adverse effects, especially when immunotherapy agents are combined.
The use of long-term immunosuppressive treatment is advocated only for patients with objectively documented improvements in an initial trial of immunotherapy. 1 In patients who regain normal cognition after immunotherapy or continue to improve after acute treatment, we recommend close continued observation without continued immunosuppression. However, long-term immunotherapy should be considered in patients who respond suboptimally, plateau clinically, or relapse. The substantial improvements reported in our study justify offering the option of long-term immunotherapy for informed patients of this type. It is important to include a corticosteroidsparing agent (such as azathioprine or mycophenolate mofetil) to minimize or possibly discontinue the use of corticosteroids. Maintenance immunotherapy is guided by symptoms reported by the patient or family members, periodic objective cognitive assessments, and medication adverse effects.
Prophylactic treatments to avert osteoporosis and Pneumocystis jiroveci infection are advised for patients requiring long-term corticosteroid therapy. Use of mycophenolate mofetil or azathioprine as a corticosteroid-sparing agent requires careful monitoring of hematologic, hepatic, and renal function indices. We generally reserve the use of cyclophosphamide, rituximab, and plasma exchange for patients refractory to or intolerant of other therapies.
As a retrospective analysis, our study introduces the risk of observer bias, and the lack of a placebo-treated group makes it difficult to determine the natural course of an immune-mediated dementia. The limited sample size precluded a multivariate logistic regression analysis, and the width of the confidence intervals for odds ratio was higher than anticipated. Another potential shortcoming of our study is the heterogeneous cohort, which encompassed patients with neuron-specific, other organ-specific, and non-organ-specific autoantibodies, as well as patients without detectable autoantibodies. We recognize that some patients may have responded to immunotherapy through suppression of a nonautoimmune inflammatory process. Nevertheless, patient heterogeneity reflects the reality of the spectrum of immunotherapy-responsive cognitive impairment encountered in a clinical setting. Although clinical, radiologic, and serologic findings are diverse, they are unified diagnostically by the response to immunotherapy. This report provides a framework for future larger studies and represents current knowledge in the field.
The diagnosis and treatment of an autoimmune dementia is often delayed, reflecting a lack of recognition of this disorder. We have outlined in a diagnostic algorithm ( Figure 6 ) a suggested stepwise approach to evaluating patients with suspected autoimmune dementia. We hope that this will assist neurologists and other physicians in identifying and managing patients with autoimmune dementia.
CONCLUSION
Autoimmune dementias are underrecognized and frequently misdiagnosed as neurodegenerative or prion disorders. Cognitive assessments by mental status examination or neuropsychological testing are helpful for documenting objective improvements after immunotherapy. This article reports objective improvements (often substantial) after an initial trial of immunotherapy in patients considered to have an irreversible neurologic disorder and maintenance of long-term remission with extended immunotherapy. Functional neuroimaging, EEG, and MRI improvements frequently correlated with clinical response to immunotherapy. Recognition of clinical and serologic clues to an autoimmune dementia allows early and sustained treatment, thus optimizing favorable neurologic outcomes.
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